...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA >Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis
【24h】

Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis

机译：在Odanacatib之后，用唑酮酸治疗预防骨质疏松症的绝经后妇女的骨质流失

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The SummaryTreatment with zoledronic acid 5mg maintained bone turnover markers in the premenopausal range, increased lumbar spine bone mineral density, and maintained hip bone mineral density in women previously treated with odanacatib 50mg weekly.IntroductionThe development of odanacatib (ODN), a cathepsin K inhibitor, for treatment of osteoporosis was discontinued due to an increased risk of cardiovascular events. As the treatment is considered reversible, participants from the LOFT trial in Aarhus, Denmark, were offered treatment with zoledronic acid (ZOL).MethodsSixty-seven postmenopausal women were treated with ZOL 5mg and followed for 12months. Of these, 39 had received ODN for 7years and 28 had received placebo for 5years and ODN for 2years. Bone turnover markers (BTM) were measured 3, 6, and 12months after ZOL, and DXA of spine and hip were performed at time of ZOL treatment and after 12months.ResultsWithin the entire study population, BMD at the lumbar spine increased by 2.80.9% (mean +/- SEM) (p<0.01) from baseline to month 12. There was no significant change in BMD at the total hip (p=0.17) or femoral neck (p=0.39). There was no difference in the changes in BMD from baseline to 12months between the two groups at any site (p0.20 for all). CTX increased by 107 +/- 9% (p<0.001), PINP by 102 +/- 16% (p<0.001), osteocalcin by 32 +/- 6% (p=0.001) and BSAP by 79 +/- 37% (p=0.001) between 3 and 12months after ZOL. At month 12, BTM were still within the premenopausal reference range. S-25-hydroxyvitamin D increased (p=0.059), while PTH (p=0.007) and eGFR (p=0.014) decreased during the year following ZOL administration.Conclusion p id=Par5 Treatment with ZOL 5mg maintained BTMs in the premenopausal range and prevented bone loss in women previously treated with ODN.
机译：唑来膦酸的5mg的保持SummaryTreatment骨转换指标在绝经前范围，增加的腰椎骨矿物质密度，并保持髋骨矿物质在妇女密度预先用50毫克odanacatib处理weekly.IntroductionThe的odanacatib发展（ODN），组织蛋白酶K抑制剂，用于治疗骨质疏松症的停产是由于心血管事件的风险增加。由于治疗被认为是可逆的，从在丹麦奥尔胡斯的LOFT试验参与者，都接受了治疗用唑来膦酸（ZOL）.MethodsSixty个绝经后妇女用ZOL处理为5mg和随访12个月。其中，39收到了ODN的7年和28收到了安慰剂5年和ODN的2年。骨转换指标（BTM）测量ZOL后3,6，和12个月，以及脊柱和髋部的DXA物在治疗ZOL时间和12months.ResultsWithin后整个研究群体进行，BMD的腰椎增加2.80.9 ％（平均值+/- SEM）（p <0.01）从基线到第12个月有在全髋关节（p值= 0.17）或股骨颈（p值= 0.39）中没有BMD变化显著。有在任何部位（P0.20所有）在BMD从基线到两组12个月的变化没有区别。 CTX增加107±9％（P <0.001），PINP由102 +/- 16％（P <0.001），骨钙素由32 +/- 6％（P = 0.001）和BSAP 79 +/- 37 ％ZOL后3和12个月之间（p = 0.001）。在第12个月，BTM仍是绝经前参考范围内。以下ZOL administration.Conclusion p ID = PAR5治疗年内S-25-羟基d增加（p = 0.059），而PTH（P = 0.007）和EGFR（p值= 0.014）降低与5毫克ZOL保持在绝经前范围的BTM而在女性预防骨质流失与以前ODN处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号